1. Home
  2. LRMR vs RCKT Comparison

LRMR vs RCKT Comparison

Compare LRMR & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Larimar Therapeutics Inc.

LRMR

Larimar Therapeutics Inc.

N/A

Current Price

$3.03

Market Cap

253.5M

Sector

Health Care

ML Signal

N/A

Logo Rocket Pharmaceuticals Inc.

RCKT

Rocket Pharmaceuticals Inc.

N/A

Current Price

$2.32

Market Cap

277.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LRMR
RCKT
Founded
N/A
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
253.5M
277.7M
IPO Year
2014
2014

Fundamental Metrics

Financial Performance
Metric
LRMR
RCKT
Price
$3.03
$2.32
Analyst Decision
Strong Buy
Buy
Analyst Count
11
14
Target Price
★ $14.40
$8.58
AVG Volume (30 Days)
1.3M
★ 1.6M
Earning Date
11-24-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 26.37
EPS
N/A
★ 0.23
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,102.46
P/E Ratio
★ N/A
$3.64
Revenue Growth
N/A
N/A
52 Week Low
$1.92
$2.17
52 Week High
$6.42
$5.45

Technical Indicators

Market Signals
Indicator
LRMR
RCKT
Relative Strength Index (RSI) 59.82 41.72
Support Level $2.89 $2.23
Resistance Level $4.19 $2.73
Average True Range (ATR) 0.25 0.19
MACD 0.09 0.02
Stochastic Oscillator 95.93 24.84

Price Performance

Historical Comparison
LRMR
RCKT

About LRMR Larimar Therapeutics Inc.

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide technology platform. Its flagship product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare genetic disease characterized by insufficient production of FXN. The company also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.

About RCKT Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.

Share on Social Networks: